JP2018516950A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516950A5
JP2018516950A5 JP2017563600A JP2017563600A JP2018516950A5 JP 2018516950 A5 JP2018516950 A5 JP 2018516950A5 JP 2017563600 A JP2017563600 A JP 2017563600A JP 2017563600 A JP2017563600 A JP 2017563600A JP 2018516950 A5 JP2018516950 A5 JP 2018516950A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
ifn
molecule
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017563600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516950A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/036925 external-priority patent/WO2016201251A1/en
Publication of JP2018516950A publication Critical patent/JP2018516950A/ja
Publication of JP2018516950A5 publication Critical patent/JP2018516950A5/ja
Priority to JP2021103895A priority Critical patent/JP2021167324A/ja
Pending legal-status Critical Current

Links

JP2017563600A 2015-06-12 2016-06-10 がん治療のための集中インターフェロン免疫療法 Pending JP2018516950A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021103895A JP2021167324A (ja) 2015-06-12 2021-06-23 がん治療のための集中インターフェロン免疫療法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562175024P 2015-06-12 2015-06-12
US201562175044P 2015-06-12 2015-06-12
US62/175,044 2015-06-12
US62/175,024 2015-06-12
US201562257852P 2015-11-20 2015-11-20
US62/257,852 2015-11-20
US201662321724P 2016-04-12 2016-04-12
US62/321,724 2016-04-12
PCT/US2016/036925 WO2016201251A1 (en) 2015-06-12 2016-06-10 Focused interferon immunotherapy for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103895A Division JP2021167324A (ja) 2015-06-12 2021-06-23 がん治療のための集中インターフェロン免疫療法

Publications (2)

Publication Number Publication Date
JP2018516950A JP2018516950A (ja) 2018-06-28
JP2018516950A5 true JP2018516950A5 (enExample) 2019-09-05

Family

ID=57504236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017563600A Pending JP2018516950A (ja) 2015-06-12 2016-06-10 がん治療のための集中インターフェロン免疫療法
JP2021103895A Pending JP2021167324A (ja) 2015-06-12 2021-06-23 がん治療のための集中インターフェロン免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021103895A Pending JP2021167324A (ja) 2015-06-12 2021-06-23 がん治療のための集中インターフェロン免疫療法

Country Status (6)

Country Link
US (1) US20180312561A1 (enExample)
EP (1) EP3307301A4 (enExample)
JP (2) JP2018516950A (enExample)
AU (2) AU2016274897B2 (enExample)
CA (1) CA2988619A1 (enExample)
WO (1) WO2016201251A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3577133A1 (en) * 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
WO2018144999A1 (en) * 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CN109810995B (zh) * 2017-12-06 2020-10-02 阿思科力(苏州)生物科技有限公司 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
CN110194800B (zh) * 2018-02-26 2022-11-18 张灏 一种融合蛋白、细胞外泌体和肿瘤疫苗及其应用
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
AU2020398327A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
KR101661770B1 (ko) * 2007-09-21 2016-10-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
US9272029B2 (en) * 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
ES2611479T3 (es) * 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
WO2012170072A1 (en) * 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
CN104203982B (zh) * 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease

Similar Documents

Publication Publication Date Title
JP2018516950A5 (enExample)
JP6966176B2 (ja) ヒトポリオウイルス受容体(pvr)に特異的な抗体
EP2970473B1 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
JP2021167324A5 (enExample)
JP7274426B2 (ja) 抗gitrアゴニスト抗体での癌の処置
HK1225634A1 (zh) 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
US20180044428A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
JP2014527814A5 (enExample)
JP2020527332A5 (enExample)
JP2019517505A (ja) リンパ腫処置における抗cd30抗体と組み合わせた抗pd−1抗体の使用
JP7606706B2 (ja) ヒトネクチン-2に特異的な抗体
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
CN113677707A (zh) 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
CN113874036A (zh) 使用cdk抑制剂的联合治疗
EP3893888A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
JP2021500320A (ja) 癌の治療のための配合剤
EP4090430A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
TW202313109A (zh) 用抗cd39抗體治療癌症之方法
RU2836467C2 (ru) Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований
JP2022527345A (ja) Pd1阻害剤及びil-17b阻害剤に基づく複合療法
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
HK1259020B (en) Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies